Fig 1: FAMIN controls DC metabolism and tunes antigen uptake and presentation without a transcriptional signature(A) Differentially expressed genes between Famin-/- and Famin+/+ BM-derived cDC1s (n = 4; GEO: GSE126473).(B) Heatmap of purine nucleotide levels in Faminp.254I, Faminp.254V, and Faminp.284R cDC1s (n = 6/5/6); for details, see Table S3.(C) Differential metabolite abundance between Faminp.254I and Faminp.284R BM-derived cDC1s; identifiable differential LC-MS features (positive and negative ionization modes) highlighted in red and annotated (n = 5).(D) Percentage AF647-OVA+Faminp.254I, Faminp.254V, or Faminp.284R splenic CD11c+ DCs following uptake of AF647-OVA for indicated times (n = 3).(E) Endosome-to-cytosol transfer in ß-lactamase-loaded Faminp.254I and Faminp.284R cDC1s (n = 6/6, from 3 mice per genotype).(F) Percentage splenic CD11c+ DCs staining positive for OVA257-264 bound to H-2Kb, after incubation with OVA257-264 for indicated times (n = 3).(G) Schematic depiction of the IMP–S-AMP–AMP cycle and IMP–XMP–GMP cycle, with relationship to FAMIN products and substrates. ADSS, adenylosuccinate synthase; ADSL, adenylosuccinate lyase; AMPD, AMP deaminase; IMPDH, IMP dehydrogenase; GMPS, GMP synthase; GMPR, GMP reductase; HPRT, hypoxanthine guanine phosphoribosyltransferase; APRT, adenine phosphoribosyltransferase, ADA, adenosine deaminase; PNP, purine nucleoside phosphorylase; MTA, methylthioadenosine; MTAP, MTA phosphorylase; SAM, S-adenosylmethionine; dcSAM, decarboxylated SAM.(H) Oxygen consumption rate (OCR) of Faminp.254I, Faminp.254V, and Faminp.284R BM-derived cDC1s. Basal OCR followed by oligomycin A (Oligo), FCCP, and rotenone plus antimycin A (Rot + Ant) (n = 16–18, from 3 mice per genotype).(I) Basal extracellular acidification rate (ECAR) of Faminp.254I, Faminp.254V, and Faminp.284R BM-derived cDC1s (n = 16–18, from 3 mice per genotype).(J) Secreted lactate levels in supernatants of Faminp.254I, Faminp.254V, and Faminp.284R splenic DCs after 3 h incubation in OptiMEM medium (n = 8–9, from 3 mice per genotype).(K) Cytoplasmic pH (pHc) of Faminp.254I, Faminp.254V, and Faminp.284R splenic DCs measured using pHrodo indicator probe (n = 12, from 3 mice per genotype).(L) Fractional labeling of cellular aspartate as [13C415N1] isotopomer in Faminp.254I, Faminp.254V, and Faminp.284R BM-derived cDC1 following a 3 h pulse with [13C4 15N1] aspartate (n = 6, from 3 mice per genotype).(M) Fractional labeling of [13C4] malate and levels of unlabeled (M+0) malate following a 3 h pulse of Faminp.254I, Faminp.254V, and Faminp.284R cDC1s with [13C4] malate (n = 9/9/5, from 3/3/2 mice per genotype).(N) Total levels of aspartate, IMP, succinyl-AMP, and AMP following a 3 h pulse of Faminp.254I, Faminp.254V, and Faminp.284R cDC1s with [13C4] malate (n = 9/9/5, from 3/3/2 mice per genotype).Data represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 (one-way ANOVA or unpaired two-tailed Student’s t test where appropriate). See also Figure S3.
Fig 2: The mouse ovariectomy model demonstrated the same purinergic pathway changing pattern compared with human females both on normal or high-fat diets, which contributed to the elevating extracellular ATP levels, leading to higher inflammation markers, myocardial fibrosis, and ultimately systolic dysfunction.A, Body weight (g), EF (%), FS (%), and calculated LV mass (mg) among four groups of mice: female mice fed with control diet (Control Diet); female ovariectomized mice, control diet (OVX); female mice with high-fat diet (HFD); female ovariectomized mice with high-fat diet (HFD + OVX). B, Quantification of purinergic pathway markers and extracellular adenosine level among four groups. C, PicoSIRIUS fibrosis staining on mice myocardial tissue. Scale bar = 100 μm. D, Quantification of inflammatory markers. Data are represented as mean ± SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001. EF = ejection fraction; FS = fractional shortening; LV = left ventricle; CD39 = cluster of differentiation 39 (ecto-nucleoside triphosphate diphosphohydrolase 1); CD73 = cluster of differentiation 73 (Ecto 5’nucleotidase); ENT-1 = equilibrative nucleoside transporter 1; ADA = adenosine deaminase; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; IL-6 = interleukin 6; MIG = Monokine induced by gamma- interferon. In A, n = 10 for each group in Body Weight, EF, FS, and LV Mass. In B, n = 10 for each group in CD39, CD73, ENT-1, and ADA, n = 4 for Purine Adenosine Assay. In C, n = 3 for Control Diet, OVX, HFD, and HFD + OVX. In D, n = 10 for each group in IL-6, MIG, and Leptin. In A, B, and D, n corresponds to one mouse. In C, n corresponds to slices from different mouse in the same group.
Fig 3: Gender differences in atrial fibrosis and myocardial Blush Grades among patients undergoing cardiac surgery correspond to the altered purinergic pathway and inflammation profile in females.A, PicoSIRIUS fibrosis staining on atrial tissue. Images taken at 20× on atrial tissue before CBP. B, myocardial Blush Grade assessed preoperatively. C, quantification of purinergic signaling markers pre- and post-CPB from human atrial tissue. (Western blotting for CD39, CD73, and ADORA2B; ADA assay for serum ADA levels). D, Immunofluorescence staining of P2X7 on atrial tissue. Scale bar = 50 μm. E and F, quantification of inflammatory markers on human samples. Data represented as median ± SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001. CBP = cardiopulmonary bypass; CD39 = cluster of differentiation 39 (ecto-nucleoside triphosphate diphosphohydrolase 1); CD73 = cluster of differentiation 73 (Ecto 5’nucleotidase); ADORA2B = adenosine receptor 2B; ADA = adenosine deaminase; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; IL-22 = interleukin 22; MDC = macrophage-derived chemokine; TNFα = tumor necrotizing factor α; ENA-78 = epithelial neutrophil-activating protein 78. In A, n = 40 for both female and male participants. In B, n = 17 for both female and male participants. In C n = 17 for each group in CD39, n = 7 for each group in CD73 and ADORA2B, n = 9 for each group in ADA. In D, n = 5 for Pre—F, Post-F, Pre-M, and Post-M in P2X7. In E, n = 19 for each group in IL-22, MDC, and TNFα. In F, n = 8 for each group in Leptin, n = 6 for each group in ENA-78. In all cases, n corresponds to one participant.
Supplier Page from Abcam for Anti-ADA antibody